中国医药
(600056)
| 流通市值：163.14亿 | | | 总市值：163.20亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 2,368,947,896.5 | 2,999,554,381.83 | 2,769,756,319.52 | 4,356,499,260.42 |
| 交易性金融资产 | 128,730,210.41 | 128,730,210.41 | 128,730,210.41 | 128,730,210.41 |
| 应收票据及应收账款 | 15,835,513,640.53 | 14,964,260,471.64 | 14,841,460,587.84 | 13,563,661,134.43 |
| 其中：应收票据 | 328,800,252.99 | 203,592,190.41 | 537,392,004.84 | 543,977,467.35 |
| 应收账款 | 15,506,713,387.54 | 14,760,668,281.23 | 14,304,068,583 | 13,019,683,667.08 |
| 应收款项融资 | 353,176,058.17 | 348,003,755.81 | 234,112,430.04 | 387,121,445.84 |
| 预付款项 | 1,007,211,521.41 | 1,120,048,675.02 | 1,063,401,420.24 | 727,984,832.57 |
| 其他应收款合计 | 1,861,667,890.3 | 1,697,815,178.16 | 1,582,067,947.08 | 1,598,962,001.08 |
| 存货 | 6,238,388,125 | 6,248,545,517.99 | 5,769,273,940.01 | 6,285,067,620.81 |
| 合同资产 | 16,281,577.15 | 27,856,201.55 | 84,287,312.19 | 56,619,943.98 |
| 一年内到期的非流动资产 | - | - | 44,210,847.2 | 46,448,446.08 |
| 其他流动资产 | 241,020,751.06 | 287,456,574.65 | 270,847,841.76 | 263,229,137.28 |
| 流动资产合计 | 28,050,937,670.53 | 27,822,270,967.06 | 26,788,148,856.29 | 27,414,324,032.9 |
| 非流动资产: | | | | |
| 长期应收款 | 11,218,240.03 | 11,120,646.38 | 14,019,004.24 | 10,623,788.41 |
| 长期股权投资 | 2,734,648,148.36 | 2,722,004,968.26 | 2,709,421,496.51 | 2,693,259,296.51 |
| 其他权益工具投资 | 47,168,046.76 | 47,168,046.76 | 47,892,962.15 | 47,168,046.76 |
| 投资性房地产 | 89,674,591.51 | 90,782,571.34 | 91,807,660.57 | 94,627,563.46 |
| 固定资产 | 2,233,545,298.48 | 2,272,556,825.81 | 2,283,830,265.74 | 2,248,743,460.43 |
| 在建工程 | 292,846,057.48 | 208,363,658.86 | 201,915,499.24 | 257,610,059.01 |
| 使用权资产 | 227,331,573.55 | 259,848,011.23 | 281,931,199.75 | 302,784,180.61 |
| 无形资产 | 711,591,566.07 | 672,045,668.76 | 671,259,331.23 | 678,489,157.75 |
| 开发支出 | 479,041,963.23 | 495,495,305.48 | 485,688,685.8 | 476,017,072.6 |
| 商誉 | 996,062,765.04 | 996,062,765.04 | 996,062,765.04 | 996,062,765.04 |
| 长期待摊费用 | 150,133,219.39 | 143,422,322.27 | 147,407,867.8 | 152,476,078.22 |
| 递延所得税资产 | 715,563,027.48 | 707,518,233.54 | 711,448,406.67 | 693,428,913.03 |
| 其他非流动资产 | 247,823,158.4 | 263,284,547.6 | 260,221,851.02 | 259,711,597.54 |
| 非流动资产合计 | 8,936,647,655.78 | 8,889,673,571.33 | 8,902,906,995.76 | 8,911,001,979.37 |
| 资产总计 | 36,987,585,326.31 | 36,711,944,538.39 | 35,691,055,852.05 | 36,325,326,012.27 |
| 流动负债: | | | | |
| 短期借款 | 4,444,016,834.96 | 4,129,091,717.07 | 4,130,903,346.39 | 4,005,522,699.55 |
| 衍生金融负债 | - | - | - | 154,794.37 |
| 应付票据及应付账款 | 9,700,720,766.34 | 9,599,411,225.99 | 8,766,519,921.33 | 8,657,830,495.55 |
| 其中：应付票据 | 1,533,524,699.21 | 1,822,637,750.45 | 1,458,044,421.81 | 1,495,912,512 |
| 应付账款 | 8,167,196,067.13 | 7,776,773,475.54 | 7,308,475,499.52 | 7,161,917,983.55 |
| 预收款项 | 2,220,611.06 | 2,789,275.63 | 2,501,360.16 | 1,351,471.78 |
| 合同负债 | 1,137,735,758.6 | 1,016,590,847.39 | 1,145,083,584.96 | 1,087,220,446.99 |
| 应付职工薪酬 | 215,942,140.08 | 185,955,647.85 | 182,063,367.92 | 256,514,841.13 |
| 应交税费 | 207,074,973.18 | 199,914,071.07 | 199,216,880.06 | 204,227,833.11 |
| 其他应付款合计 | 2,884,092,475.45 | 3,062,119,549.7 | 2,532,377,049.31 | 2,829,066,088.73 |
| 应付股利 | 15,254,533.95 | 130,562,628.01 | 2,440,527.59 | 5,435,337.53 |
| 一年内到期的非流动负债 | 852,526,565.71 | 1,267,652,199.87 | 93,378,155.08 | 700,255,146.13 |
| 其他流动负债 | 203,848,888.72 | 189,965,873.55 | 171,714,473.17 | 260,149,802.9 |
| 流动负债合计 | 19,648,179,014.1 | 19,653,490,408.12 | 17,223,758,138.38 | 18,002,293,620.24 |
| 非流动负债: | | | | |
| 长期借款 | 867,500,000 | 719,800,000 | 1,894,256,829.3 | 1,553,356,829.3 |
| 租赁负债 | 183,305,474 | 201,883,162.05 | 207,444,786.04 | 187,914,681 |
| 长期应付款 | 1,873,173,051.47 | 1,883,675,795.65 | 1,889,671,029.18 | 2,126,159,509.38 |
| 长期应付职工薪酬 | 15,108,087.8 | 15,510,796.45 | 16,599,626.18 | 16,448,768.61 |
| 递延收益 | 65,111,229.72 | 65,385,547 | 63,751,643.56 | 65,383,338.12 |
| 递延所得税负债 | 44,303,269.71 | 44,233,386.58 | 56,258,529.53 | 44,201,985.72 |
| 非流动负债合计 | 3,048,501,112.7 | 2,930,488,687.73 | 4,127,982,443.79 | 3,993,465,112.13 |
| 负债合计 | 22,696,680,126.8 | 22,583,979,095.85 | 21,351,740,582.17 | 21,995,758,732.37 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,495,879,748 | 1,495,879,748 | 1,495,879,748 | 1,495,879,748 |
| 资本公积 | 1,799,105,055.7 | 1,799,105,055.7 | 2,084,126,755.08 | 2,101,175,055.7 |
| 其他综合收益 | 1,706,154.59 | 3,720,973.91 | 1,977,145.84 | 1,092,168.55 |
| 盈余公积 | 630,553,833.6 | 630,553,833.6 | 613,257,225.23 | 630,553,833.6 |
| 未分配利润 | 7,925,711,711.58 | 7,794,316,201.7 | 7,792,539,328.46 | 7,803,931,077.54 |
| 归属于母公司股东权益合计 | 11,852,956,503.47 | 11,723,575,812.91 | 11,987,780,202.61 | 12,032,631,883.39 |
| 少数股东权益 | 2,437,948,696.04 | 2,404,389,629.63 | 2,351,535,067.27 | 2,296,935,396.51 |
| 股东权益合计 | 14,290,905,199.51 | 14,127,965,442.54 | 14,339,315,269.88 | 14,329,567,279.9 |
| 负债和股东权益合计 | 36,987,585,326.31 | 36,711,944,538.39 | 35,691,055,852.05 | 36,325,326,012.27 |
| 公告日期 | 2025-10-28 | 2025-08-28 | 2025-04-30 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |